{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035544","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.958882+00:00","generated_at":"2026-06-04T15:15:11.510108+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avenue Therapeutics reports FY2023 net loss of $10.5M; AJ201 Phase 1b/2a enrollment complete, topline data Q2 2024","bullets":["Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.","Completed enrollment in AJ201 Phase 1b/2a for SBMA (25 patients); topline data expected Q2 2024.","Reached final agreement with FDA on Phase 3 safety study protocol for IV tramadol; aims to initiate pending financing.","Nasdaq granted extension to May 20, 2024 to meet continued listing requirements.","Raised $5.0M gross in January 2024 via warrant inducement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035544","json":"https://secwatch.observer/filing/0001104659-24-035544.json","markdown":"https://secwatch.observer/filing/0001104659-24-035544.md","text":"https://secwatch.observer/filing/0001104659-24-035544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/tm248747d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:15:11.510108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56f3d16f1a30077d06b7b7b8c350b3c942dcead0","claim":"AVENUE THERAPEUTICS, INC. reported the fiscal year ended December 31, 2023 results: net income Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63, EPS $0.98 per share.","evidence_excerpt":"Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63 per share, in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63"},{"label":"EPS","value":"$0.98 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}